Drug Index


Mechanism :

The mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA.

Indication :

  • Hodgkin’s lymphoma
  • Gliomas
  • Medulloblastoma

Contraindications :

Contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration. Due consideration of this possible state should be given to each patient who has leukopenia, thrombocytopenia or anemia. Full blood count should be satisfactory before commencing treatment.

Dosing :

Always consult the current treatment protocol for details of dosage and scheduling.
Hodgkin’s disease:
Oral 50 mg/m² daily for 7 days; increase to 100 mg/m² until maximum response is achieved or leukopenia/thrombocytopenia ensues.

Adverse Effect :

Myelosuppression, nausea, vomiting, diarrhea, CNS toxicity (paraesthesia, ataxia, dizziness, headaches, nightmares, depression and insomnia), and hallucinations are common. Rarely, pulmonary toxicity, possibly because of hypersensitivity reaction; nystagmus, diplopia, papilledema and photophobia.

Interaction :

No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
Procarbazine: May exacerbate respiratory depression, if taken in conjunction with CNS depressants.
Antidepressants and Sympathomimetics: Procarbazine has weak MAOI activity and may precipitate hypertensive crisis, agitation and tremors if taken in conjunction with some antidepressants and sympathomimetics. Avoid tyramine-containing foods e.g. cheese, marmite etc.
Alcohol: A disulfiram-type reaction may occur if taken with alcohol and CNS depression may be accentuated.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-5050–100% of dose
10-2050–100% of dose. Use with caution
<1050–100% of dose. Use with caution

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

Pre-existing severe hepatic impairment:
Use is not recommended.

If hepatotoxicity develops during therapy and based on adult data:
If liver transaminases levels are between 1.6 and 6 times the upper limit of normal (ULN): Reduce dose by 1/4th.
If liver transaminases levels reach greater than 6 times the ULN: use with caution, apply clinical judgement.
If serum bilirubin is greater than 5 mg/dL and liver transaminases levels are greater than >3 times the ULN: use is not recommended.
03/24/2024 11:17:46 Procarbazine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0